Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VBP-926 for Chemotherapy-associated Paronychia
NCT03207906Phase 2Completed
- Sponsor
- Veloce BioPharma
- Start
- Oct 2017
- Primary completion
- Jul 2018
- Modality
- Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of IVIEW-1502 in paronychia (3 arms), sponsored by Veloce BioPharma. Primary endpoint: Downgrading of the 6-point Paronychia Severity Grading scale at 8 weeks. Started Oct 2017; status: completed.
02
Drugs
IVIEW-1502
03
Conditions
paronychia
Beyond the preview
Go deeper on NCT03207906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03207906.